Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

192 results about "Nucleic Acid Testing" patented technology

Nucleic acid testing (NAT) is a molecular technique for screening blood donations to reduce the risk of transfusion transmitted infections (TTIs) in the recipients, thus providing an additional layer of blood safety.

Constant temperature synchronous amplification detecting process for nucleic acid and use thereof

The invention discloses a constant temperature synchronous amplified detection method of nucleic acid as well as an application thereof. The method comprises the following steps of: 1) mixing reactants containing the following components: a. a nucleic acid sample under test; b. a primer 1: a 3`-terminal of the primer can be hybridized at a 3`-terminal or near the 3`-terminal of the nucleic acid sample under test, and a 5`-terminal is a promotor sequence; c. a primer 2: the primer can be hybridized with a 5`-terminal of a negative strand of the nucleic acid sample under test; d. one or a plurality of fluorescent probes; e. at least one DNA polymerase relied by RNA; and f. at least one RNA polymerase that can identify the promotor sequence; and 2) carrying out the constant temperature amplification reaction to the mixed reactants in a closed vessel, detecting the changes of fluorescence signals in a reaction system synchronously by a detector, and conducting the quantitative and qualitative detection to the nucleic acid sample according to the time and intensity of fluorescence signal changing. The method and the application have the advantages of low pollution, constant temperature in the reaction process, high detection sensitivity, fast detection speed, low requirements on equipment and instrument and low cost, and are applied to nucleic acid testing in fields such as clinical examination and blood screening.
Owner:SHANGHAI RENDU BIOTECH

Digital isothermal nucleic acid detecting device and detecting method thereof

The invention provides a digital isothermal nucleic acid detecting device which comprises a micro-fluidic chip, a temperature control system and a pressure driving system. A microfluidic channel for microsphere forming and a reaction section for nucleic acid amplification are formed by the micro-fluidic chip through sequential laminating of a substrate layer, a channel layer arranged on the substrate layer and a cover plate layer arranged on the channel layer. The temperature control system comprises a lower press plate for applying pressure to the substrate from bottom to top and an upper press plate for applying pressure to the cover plate layer from top to bottom, and temperature sensing chips and temperature control heating elements for heating the reaction section are arranged in the upper press plate and the lower press plate. The pressure driving system is connected to the micro-fluidic chip and used for applying pressure to the channel layer in the micro-fluidic chip so that liquid to be detected can flow into the reaction section from the inflow end. According to the scheme, microsphere preparation and nucleic acid amplification and detection are integrated through the digital isothermal nucleic acid detecting device and the detection method, and the advantages of being high in sensitivity and the like are achieved.
Owner:SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI

crRNA (Clustered Regularly Interspaced Short Palindromic Repeat-Derived Ribonucleic Acid) for specifically detecting exon mutation of human KRAS genes #2 and #3 based on CRISPR technique

The invention discloses crRNA (Clustered Regularly Interspaced Short Palindromic Repeat-Derived Ribonucleic Acid) for specifically detecting exon mutation of human KRAS genes #2 and #3 based on a CRISPR technique. The crRNA is characterized by comprising a CRISPR-Cas13a system as well as crRNA, wherein the crRNA can be combined with the CRISPR-Cas13a system; and the crRNA has a sequence format of5'-Cas13a protein anchoring sequence-crRNA guide sequence-3'. The crRNA has the advantages that according to detection results, whether the human KRAS gene have mutation or not can be judged intuitively through fluorescent reading, high-flux sequencing can be avoided, and the crRNA has the advantages of being low in cost, possible in multi-time detection, high in detection speed, possible in direct result analysis, and the like, and is applicable to large-scale clinical sample detection; the nucleic acid testing technique disclosed by the invention is different from a conventional detection technique which is based on PCR (Polymerase Chain Reaction) techniques, and no complex temperature control instrument or system is needed in a whole reaction process; and three steps of reactions are carried out in a same reaction system, so that operation procedures can be further simplified, and nucleic acid fragments with specific sequences can be detected within two hours.
Owner:江苏博嘉生物医学科技有限公司

Method for semi-quantitatively detecting pathogenic nucleic acid by adding internal control nucleic acid

InactiveCN101957373AAvoid diagnostic problems that are prone to false negativesAvoid problems prone to false negativesMicrobiological testing/measurementMaterial analysisTest sampleQuality control
The invention belongs to the field of nucleic acid detection and discloses a method for semi-quantitatively detecting pathogenic nucleic acid by adding internal control nucleic acid. Corresponding internal control is added in the whole process of extracting and amplifying target nucleic acid and testing by using a test paper, so that the internal control and a target segment are parallelly operated, and the semi-quantitative detection is performed finally through color development and intensity contrast of three strips, namely a detection line, an internal control line and a quality control line on the test paper. In the method, in the whole process of processing the target nucleic acid, the corresponding internal control is taken as a positive contrast, and false negative results due to links such as extraction, amplification or sample application errors are avoided in the processing of detecting by using the test paper. Meanwhile, by comparing color development intensity of the internal control line and a sample line and introducing the semi-quantitative function on the basis of the qualitative function of the immunochromatographic test paper to estimate the copy number of tested samples, the detection results are more detailed, accurate and reliable. The method has the advantages of convenient and quick operation and capacity of meeting the actual clinical requirement.
Owner:HUADONG RES INST FOR MEDICINE & BIOTECHNICS

COVID-19 nucleic acid testing primer probe composition, COVID-19 nucleic acid testing kit and COVID-19 nucleic acid testing method

The invention relates to the field of the biological technology and the medical examination technology, and provides a COVID-19 nucleic acid testing primer probe composition, a COVID-19 nucleic acid testing kit and a COVID-19 nucleic acid testing method for solving the problems of low accuracy, poor specificity and low sensitivity of a traditional virus nucleic acid testing method. The COVID-19 nucleic acid testing primer probe composition comprises a first primer probe group, a second primer probe group and a third primer probe group, wherein the first primer probe group comprises a forward primer ORF1ab-F, a probe ORF1ab-P and a reverse primer ORF1ab-R; the second primer probe group comprises a forward primer N-F, a probe N-P and a reverse primer N-R; and the third primer probe group comprises a forward primer Rpp30-F, a probe Rpp30-P and a reverse primer Rpp30-R. According to the primer probe composition disclosed by the invention, through artful design of an amplification primer pair and a detection probe, mutual interference between a plurality of primer pairs and corresponding detection probes is avoided. The kit has a simple structure, an interior label is used for monitoring a collection, transportation and extraction process of a sample to be detected, and the false negative of a detection result is avoided.
Owner:SHANGHAI CHROMYSKY MEDICAL RES +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products